AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1936012
Drug: Molsidomine 8
RxNorm normalized name: molsidomine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine 8 mg t.i.d.
Trial: 7423136
Drug: Euphyllin retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphyllin retard (theophylline slow‐releasing coated tablets)
Trial: 31819405
Drug: Erdosteine 300
RxNorm normalized name: erdosteine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine 300 mg twice daily (n=126)
Trial: 17374706
Drug: Oral ethinyl
RxNorm normalized name: ethinyl estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ethinyl estradiol (15 microg/d)
Trial: 12466695
Drug: Pseudoephedrine (PSE)
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine (PSE) 120 mg
Trial: 9651906
Drug: Pravastatin and
RxNorm normalized name: pravastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin and hormone replacement therapy (HRT) (MC group)
Trial: 8209274
Drug: Mitomycin/ifosfamide/cisplatin chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin/ifosfamide/cisplatin chemotherapy plus surgery
Trial: 3057850
Drug: atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 50 or 100 mg
Trial: 3057850
Drug: nadolol 40
RxNorm normalized name: nadolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nadolol 40 or 80 mg
Trial: 3057850
Drug: both beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both beta blockers
Trial: 24119735
Drug: Entecavir antiviral
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir antiviral treatment (group A)
Trial: 19288903
Drug: Acupuncture (encircling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (encircling acupuncture around affected focus, common acupuncture at Hegu (LI 4), Xuehai (SP 10), Fenglong (ST 40), Sanyinjiao (SP 6), venesection and cupping twice a week)
Trial: 19288903
Drug: Isotretinoin Capsules
RxNorm normalized name: Isotretinoin Capsules
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin Capsules (10 mg, t.i.d.)
Trial: 19288903
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (acupuncture and Western medicine)
Trial: 12780424
Drug: Advice plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice plus iron supplement (60 mg Fe2+ or 3.6 mg heme iron plus 24 mg Fe2+)
Trial: 12780424
Drug: Advice plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice plus iron supplement (3.6 mg heme iron plus 24 mg Fe2+)
Trial: 1995766
Drug: High-level IgG
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-level IgG substitution (6 g l-1)
Trial: 1995766
Drug: Low-level IgG
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level IgG substitution (3 g l-1)
Trial: 24661167
Drug: Alcohol (0.80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.80 g/kg ETOH)
Trial: 22159148
Drug: Acute EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute EPO administration (30,000 IU/d for 3 days)
Trial: 22159148
Drug: Chronic EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic EPO administration (5000 IU/week for 13 weeks)
Trial: 20670234
Drug: mivacurium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mivacurium 0.25 mg.kg(‐1) (Group Miva)
Trial: 20670234
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 0.12 ml.kg(‐1) (Group Control)
Trial: 17515023
Drug: Acupuncture as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture as an adjunct therapy for IVF
Trial: 31004066
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (OAs)
Trial: 7635996
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravenous bolus dose of triazolam
Trial: 7635996
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg oral doses of triazolam
Trial: 7635996
Drug: 0.20 mg
RxNorm normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg oral dose of triazolam
Trial: 7635996
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg oral dose of triazolam
Trial: 7635996
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg oral doses of triazolam
Trial: 71604
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine during the first 6 postoperative days
Trial: 71604
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine (consecutively treated)
Trial: 21084254
Drug: Bone turnover
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone turnover markers (OC, BALP, CTX) before treatment
Trial: 21084254
Drug: Bone turnover
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone turnover markers during chemotherapy
Trial: 21084254
Drug: Bone turnover
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone turnover markers after therapy
Trial: 19032727
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg kg(‐1) dexibuprofen
Trial: 19032727
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg kg(‐1) dexibuprofen
Trial: 19032727
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg kg(‐1) ibuprofen
Trial: 12495164
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care provided by a pharmacist‐managed hypertension clinic
Trial: 9803103
Drug: 21 G
RxNorm normalized name: Long's Lancets, 21 ga
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 G needle
Trial: 9803103
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 21 G and 23 G needles
Trial: 9803103
Drug: 21 G
RxNorm normalized name: Long's Lancets, 21 ga
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 G needle and 23 G needle
Trial: 8572624
Drug: Adjuvant perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant perioperative portal liver infusion with fluorouracil, mitomycin and heparin
Trial: 8572624
Drug: Adjuvant subclavian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant subclavian intravenous infusion with fluorouracil, mitomycin and heparin
Trial: 8572624
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant treatment (Control group)
Trial: 2510054
Drug: Cefazedone (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazedone (single-dose prophylactic administration)
Trial: 31554943
Drug: Conbercept (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conbercept (0.2 ml)
Trial: 31554943
Drug: 5‐fluorouracil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (0.2 ml)
Trial: 24916013
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C plus B vitamins (400 µg folic acid, 2 mg B6, and 10 µg B12)
Trial: 24916013
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (50 mg; control group)
Trial: 17109336
Drug: Study vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study vaccine at 2 mg (n=5)
Trial: 17109336
Drug: Study vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study vaccine at 4 mg (n=20)
Trial: 17109336
Drug: Study vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study vaccine at 8 mg (n=15)
Trial: 15236274
Drug: Mercaptopurine 75
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mercaptopurine 75 mg/m2 daily
Trial: 15236274
Drug: Mercaptopurine 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mercaptopurine 37.5 mg/m2 twice daily
Trial: 15236274
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of daily vs twice daily dosing
Trial: 12174398
Drug: Community-based health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based health promotion interventions; specific details on dosage and duration not available.
Trial: 9401427
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 200 mg caffeine and a short nap
Trial: 8185426
Drug: Hydralazine hydrochloride‐isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine hydrochloride‐isosorbide dinitrate combination therapy
Trial: 8185426
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (digoxin and diuretic therapy)
Trial: 3583499
Drug: Atropine infusion
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine infusion with Method A
Trial: 3583499
Drug: Atropine infusion
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine infusion with Method B
Trial: 24709463
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin (BLF) 100 mg/day
Trial: 24709463
Drug: Bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine lactoferrin (BLF) 100 mg/day + Lactobacillus rhamnosus GG (LGG) 6×10(9) CFU/day
Trial: 19043378
Drug: S(+)‐ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine (2 mg x kg(‐1) x h(‐1); group A; n=27)
Trial: 15530134
Drug: ER-tolterodine with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER-tolterodine with antacid
Trial: 15530134
Drug: ER-tolterodine without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ER-tolterodine without antacid
Trial: 15530134
Drug: ER-oxybutynin with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER-oxybutynin with antacid
Trial: 15530134
Drug: ER-oxybutynin without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ER-oxybutynin without antacid
Trial: 7934985
Drug: Glucose alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose alone (GLUC) 4.1 mg/kg/min, n = 8
Trial: 7934985
Drug: Glucose with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose with amino acids (TPN) 275 mg N/kg/d, n = 10
Trial: 3300045
Drug: Trimethoprim (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (2 X 200 mg for 10 days)
Trial: 3300045
Drug: Cotrimoxazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (2 X 160 mg Trimethoprim + 800 mg Sulphamethoxazole for 10 days)
Trial: 30098861
Drug: Inhaled milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled milrinone (50 µg/kg)
Trial: 30098861
Drug: Inhaled levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled levosimendan (24 µg/kg)
Trial: 26563405
Drug: Rehabilitation programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation programme in addition to high-dose methylprednisolone (HDMP)
Trial: 26563405
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy alone (HDMP)
Trial: 20843662
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional therapy)
Trial: 16357191
Drug: Very well
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very well done meat consumption (>10 g/d)
Trial: 11241462
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) given in different three-dose schedules
Trial: 11241462
Drug: Inactivated poliovirus
RxNorm normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliovirus vaccine (IPV) given at 18 months
Trial: 11241462
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group immunized with the current schedule (first dose at 6 months)
Trial: 11241462
Drug: Maternal antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal antibodies present at the time of the first dose
Trial: 31133144
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (250 mg twice daily) with topical 3% tranexamic acid (twice daily)
Trial: 31133144
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (250 mg twice daily) with topical 20% azelaic acid (daily)
Trial: 21868616
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid levels (measured in mg/dl)
Trial: 21868616
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid ≤8.2 mg/dl
Trial: 8101194
Drug: Terazosin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (5 mg once daily)
Trial: 29799827
Drug: HARDL (HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HARDL (HA gel with lidocaine)
Trial: 29799827
Drug: HAJUP (HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAJUP (HA gel without lidocaine)
Trial: 27115157
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (6 g/day for 8 weeks)
Trial: 27115157
Drug: Medium-chain triglycerides
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-chain triglycerides (MCT) oil (6 g/day for 8 weeks)
Trial: 25273342
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus chemotherapy (15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks)
Trial: 22447880
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow mononuclear cells (BMCs) transendocardial injection (100 million BMCs)
Trial: 20131246
Drug: Rituximab (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1,000 mg)
Trial: 19115423
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) plus taper
Trial: 19115423
Drug: Group support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group support (GS) plus taper
Trial: 19115423
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (taper only) plus physician counselling
Trial: 12597653
Drug: Bifenthrin 100
RxNorm normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifenthrin 100 mg/m2
Trial: 12597653
Drug: Bifenthrin 200
RxNorm normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifenthrin 200 mg/m2
Trial: 12597653
Drug: Bifenthrin 50
RxNorm normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifenthrin 50 mg/m2
Trial: 12597653
Drug: Bifenthrin 25
RxNorm normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifenthrin 25 mg/m2
Trial: 12597653
Drug: Malathion 2
RxNorm normalized name: Malathion
DrugBank: Malathion (DB00772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Malathion 2 g/m2
Trial: 12597653
Drug: Bifenthrin 25
RxNorm normalized name: Bifenthrin
DrugBank: Bifenthrin (DB15056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifenthrin 25 mg/m2 and 50 mg/m2
Trial: 1906808
Drug: Bromocriptine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine with levodopa (combination therapy)
Trial: 24948586
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan 200 mg/m(2) plus salvage ASCT
Trial: 24948586
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (400mg/m(2) per week for 12 weeks)
Trial: 24948586
Drug: PAD induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAD induction therapy
Trial: 22101219
Drug: Study agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study agent
Trial: 17404152
Drug: Paclitaxel (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (225 mg/m(2) over 3 h every 3 weeks)
Trial: 9572635
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of prednisolone for the first six months, followed by lower doses thereafter
Trial: 9572635
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose glucocorticoid schedule after initial high doses
Trial: 2657953
Drug: Paraghurt tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraghurt tablets (freeze‐dried culture of Streptococcus faecium)
Trial: 22406043
Drug: Sufentanil 0.2
RxNorm normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.2 ng/mL
Trial: 22406043
Drug: Sufentanil 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.3 ng/mL
Trial: 22406043
Drug: Sufentanil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.4 ng/mL
Trial: 17063980
Drug: Meloxicam 15
RxNorm normalized name: meloxicam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 15 mg (Merck S.A. Indústrias Químicas)
Trial: 17063980
Drug: Movatec 15
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Movatec 15 mg (control formulation)
Trial: 14670782
Drug: Dexamethasone as
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone as adjuvant therapy
Trial: 10966840
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg FCHG49 glucosamine HCl, 800 mg TRH122 low molecular weight sodium chondroitin sulfate and 152 mg manganese ascorbate twice daily (Cosamin DS)
Trial: 8867164
Drug: Peribulbar injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar injection
Trial: 6422735
Drug: Propranolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol plus lidoflazine (L)
Trial: 6422735
Drug: Propranolol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol plus lidoflazine (L) after crossover
Trial: 6422735
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Propranolol + Lidoflazine)
Trial: 25803256
Drug: Flexible regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible regimen of daily risedronate (5 mg)
Trial: 25803256
Drug: Fixed regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed regimen of daily risedronate (5 mg)
Trial: 18240234
Drug: Oral azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azathioprine (AZA)
Trial: 18240234
Drug: Intravenous pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pulse cyclophosphamide (CYC)